



# CRISPR Screen Reveals that EHEC's T3SS and Shiga Toxin Rely on Shared Host Factors for Infection

## Citation

Pacheco, Alline R., Jacob E. Lazarus, Brandon Sit, Stefanie Schmieder, Wayne I. Lencer, Carlos J. Blondel, John G. Doench, Brigid M. Davis, and Matthew K. Waldor. 2018. "CRISPR Screen Reveals that EHEC's T3SS and Shiga Toxin Rely on Shared Host Factors for Infection." *mBio* 9 (3): e01003-18. doi:10.1128/mBio.01003-18. <http://dx.doi.org/10.1128/mBio.01003-18>.

## Published Version

doi:10.1128/mBio.01003-18

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:37298516>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)



# CRISPR Screen Reveals that EHEC's T3SS and Shiga Toxin Rely on Shared Host Factors for Infection

Aline R. Pacheco,<sup>a,b</sup> Jacob E. Lazarus,<sup>a,b,c</sup> Brandon Sit,<sup>a,b</sup> Stefanie Schmieder,<sup>d,e,f</sup> Wayne I. Lencer,<sup>d,e,f</sup> Carlos J. Blondel,<sup>a,b\*</sup> John G. Doench,<sup>g</sup> Brigid M. Davis,<sup>a,b</sup> Matthew K. Waldor<sup>a,b,g,h</sup>

<sup>a</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA

<sup>b</sup>Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA

<sup>c</sup>Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA

<sup>d</sup>Division of Gastroenterology, Boston Children's Hospital, Boston, Massachusetts, USA

<sup>e</sup>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA

<sup>f</sup>Department of Pediatrics, Harvard Digestive Diseases Center, Boston, Massachusetts, USA

<sup>g</sup>Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

<sup>h</sup>Howard Hughes Medical Institute, Boston, Massachusetts, USA

**ABSTRACT** Enterohemorrhagic *Escherichia coli* (EHEC) has two critical virulence factors—a type III secretion system (T3SS) and Shiga toxins (Stxs)—that are required for the pathogen to colonize the intestine and cause diarrheal disease. Here, we carried out a genome-wide CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats with Cas9) loss-of-function screen to identify host loci that facilitate EHEC infection of intestinal epithelial cells. Many of the guide RNAs identified targeted loci known to be associated with sphingolipid biosynthesis, particularly for production of globotriaosylceramide (Gb3), the Stx receptor. Two loci (TM9SF2 and LAPTM4A) with largely unknown functions were also targeted. Mutations in these loci not only rescued cells from Stx-mediated cell death, but also prevented cytotoxicity associated with the EHEC T3SS. These mutations interfered with early events associated with T3SS and Stx pathogenicity, markedly reducing entry of T3SS effectors into host cells and binding of Stx. The convergence of Stx and T3SS onto overlapping host targets provides guidance for design of new host-directed therapeutic agents to counter EHEC infection.

**IMPORTANCE** Enterohemorrhagic *Escherichia coli* (EHEC) has two critical virulence factors—a type III secretion system (T3SS) and Shiga toxins (Stxs)—that are required for colonizing the intestine and causing diarrheal disease. We screened a genome-wide collection of CRISPR mutants derived from intestinal epithelial cells and identified mutants with enhanced survival following EHEC infection. Many had mutations that disrupted synthesis of a subset of lipids (sphingolipids) that includes the Stx receptor globotriaosylceramide (Gb3) and hence protect against Stx intoxication. Unexpectedly, we found that sphingolipids also mediate early events associated with T3SS pathogenicity. Since antibiotics are contraindicated for the treatment of EHEC, therapeutics targeting sphingolipid biosynthesis are a promising alternative, as they could provide protection against both of the pathogen's key virulence factors.

**KEYWORDS** CRISPR screen, EHEC, EPEC, LAPTM4A, Shiga toxin, T3SS, TM9SF2, host susceptibility, sphingolipid synthesis

Enterohemorrhagic *Escherichia coli* (EHEC) is a foodborne human pathogen that causes diarrheal illness worldwide. Infection is often associated with bloody diarrhea that is usually self-limited; however, 5 to 7% of cases progress to hemolytic-uremic syndrome (HUS), a life-threatening complication that can result in renal failure and

Received 5 May 2018 Accepted 9 May 2018 Published 19 June 2018

**Citation** Pacheco AR, Lazarus JE, Sit B, Schmieder S, Lencer WI, Blondel CJ, Doench JG, Davis BM, Waldor MK. 2018. CRISPR screen reveals that EHEC's T3SS and Shiga toxin rely on shared host factors for infection. mBio 9:e01003-18. <https://doi.org/10.1128/mBio.01003-18>.

**Editor** Eric J. Rubin, Harvard School of Public Health

**Copyright** © 2018 Pacheco et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Matthew K. Waldor, [mwaldor@research.bwh.harvard.edu](mailto:mwaldor@research.bwh.harvard.edu).

\* Present address: Carlos J. Blondel, Institute of Biomedical Sciences, Universidad Autónoma de Chile, Santiago, Chile.

This article is a direct contribution from a Fellow of the American Academy of Microbiology. Solicited external reviewers: Cammie Lesser, Massachusetts General Hospital; Laurie Comstock, Brigham and Women's Hospital/Harvard Medical School.

neurological sequelae (1). EHEC pathogenesis shares many features with that of enteropathogenic *E. coli* (EPEC), another extracellular pathogen that colonizes the intestine. Successful colonization by both species is dependent upon a type III secretion system (T3SS) that enables tight adherence of bacteria to host epithelial cells by inducing characteristic actin cytoskeletal rearrangements and loss of microvillus structure (attaching and effacing [AE] lesions) (2). EHEC virulence is also markedly shaped by production of Shiga toxins (Stxs), variants of which are often present in multiple copies within the EHEC genome. Translocation of Stxs to tissues outside the intestinal tract is thought to underlie the development of HUS (3, 4).

The EHEC T3SS injects a plethora of effector proteins into host cells, resulting in alteration or disruption of numerous host cell processes. During infection, EHEC is thought to target epithelial cells within the large intestine; however, a variety of cultured cell lines have been used to characterize the activity of this system. *In vivo* and *in vitro* studies have revealed that a key effector is the translocated intimin receptor (Tir) (5). Tir is inserted into the host cell membrane and serves as a receptor for the bacterial adhesin intimin (6). Interactions between intimin and Tir are also required for recruitment and rearrangement of actin and other cytoskeletal proteins underneath adherent bacteria, which results in characteristic actin-rich “pedestals.” In animal models, deletions of *tir* or *eae* (the intimin locus) and mutations that render the T3SS inactive markedly reduce the pathogen’s capacity to colonize the intestine and cause disease (7, 8).

Thirty-eight bacterial proteins in addition to Tir have been confirmed as type 3 secreted effector proteins in EHEC (9). Unlike structural components of the T3SS, individual effector proteins are frequently not essential for bacterial virulence; although their roles have not been fully defined, it is clear that effector proteins can act in redundant, synergistic, and antagonistic fashions (10). Key host processes modulated by EHEC effectors include innate immunity, cytoskeletal dynamics, host cell signaling, and apoptosis (11). EHEC effectors also restrict host cell phagocytosis of this extracellular pathogen. Effectors undergo an ordered translocation, and after its translocation, the effector protein EspZ functions as a “translocation stop” that prevents unlimited effector translocation and reduces infection-associated cytotoxicity (12). Compared to wild-type (wt) infection, *in vitro* infection with *espZ*-deficient strains results in greater host cell detachment, loss of membrane potential, and formation of condensed nuclei (13).

Although Stxs are pivotal to EHEC pathogenesis, the effects of these AB<sub>5</sub> toxins on the intestinal epithelium *per se* are not entirely clear. Toxicity was initially thought to be largely restricted to tissues beyond the intestinal tract (e.g., microvascular endothelial cells within the kidneys and the brain in the setting of HUS) (14); however, more recent *in vivo* and *ex vivo* studies suggest that Stx intoxication may also occur in the intestine at the primary site of infection. Although at low levels, receptors for Stx are present within human colonic epithelial cells (15), and Stx2 causes extensive cell death to the intestinal mucosa (16, 17). Furthermore, oral administration of Stx can lead to diarrhea in animals, and in several animal models of EHEC intestinal disease, severe diarrhea is dependent on Stx (8, 17).

The principal receptor for most forms of Stx (including Stx1 and Stx2, which are produced by the EHEC strain used in this study) is a neutral glycosphingolipid, globotriaosylceramide (Gb3). Following binding of Stx to Gb3, the toxin is internalized and undergoes retrograde transport through early endosomes, the Golgi complex, and the endoplasmic reticulum (ER); the A subunit is cleaved by furin in the Golgi complex, followed by disulfide bond reduction in the ER that releases the catalytically active A1 fragment, which undergoes retro-translocation into the cytosol (18). Site-specific depurination of 28S rRNA by the toxin results in inhibition of protein synthesis and can induce the ribotoxic stress response, the unfolded protein response, and apoptosis (19–22).

Analyses of EHEC pathogenesis have primarily focused upon identification and characterization of bacterial factors rather than on host factors required for pathoge-

nicity. Though some host factors, particularly those required for the actions of Stx and of the T3SS effectors, have been identified, to date, unbiased genome-wide screens for EHEC susceptibility loci have not been reported. Recently, such screens have become possible, given the advent of CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats with Cas9)-based libraries of host mutants whose composition can be monitored using high-throughput DNA sequencing. We recently used this approach to screen for host factors that mediate susceptibility to *Vibrio parahaemolyticus*' two T3SSs and identified several host processes not previously linked to T3SS activity (23). The efficiency and power of this approach (24, 25) prompted us to adopt this approach to identify mutants with heightened resistance to EHEC.

Here, we identify and characterize intestinal epithelial cell mutants that become enriched following library infection with an EHEC strain producing an active T3SS as well as Stx. Although minimal overlap between the action of the T3SS and Stx has previously been reported, we identified several host loci and processes that are required for the effects of both virulence factors. Genes required for production of the Stx receptor Gb3 and other sphingolipids were also found to be necessary for translocation of T3SS effectors into host cells. Additionally, we identified 2 minimally characterized loci not previously linked to either T3SS or Stx response pathways and find that they are critical for the biogenesis of host cell Gb3 and hence susceptibility to EHEC infection.


## RESULTS

### CRISPR/Cas9 screen for host factors conferring susceptibility to EHEC infection.

We developed a genome-wide CRISPR/Cas9 screen to identify host factors that contribute to susceptibility to EHEC infection in the HT-29 colonic epithelial cell line using the Avana library of single-guide RNAs (sgRNAs) (23). This library contains four sgRNAs targeting each of the annotated human protein-coding genes (26). Host cells were infected with a  $\Delta espZ$  derivative of EHEC strain EDL933 (which carries genes encoding both Stx1 and Stx2). The  $\Delta espZ$  mutation heightens T3SS activity and increases host cell death associated with infection by EHEC (13) (see Fig. S1A in the supplemental material). We anticipated that if we could increase the toxicity of the EHEC T3SS (Fig. S1B), we would enhance the screen's selective pressure and yield greater enrichment of host cell mutants resistant to this key virulence system. Although Stx1 and Stx2 were also produced under infection conditions (Fig. S1C), initial toxicity assays using purified toxin suggested that they would not exert substantial selective pressure during the screen. In contrast to infection of cells with  $\Delta espZ$  EHEC, which resulted in marked (~80%) host cell death by the end of the infection period (Fig. 1A and B), a corresponding 6-h treatment of cells with purified toxin exceeding the amount detected during infection had minimal effect on viability (Fig. S1D).

For the screen, two biological replicates of libraries of HT-29 cells mutagenized with the Avana guide RNAs were infected for 6 h with  $\Delta espZ$  EHEC at an multiplicity of infection (MOI) of 100 (Fig. 1A). Following infection, resistant cells were cultured in the presence of antibiotics until reaching ~70% confluence (~5 days) and then reseeded and reinfected. Genomic DNA (gDNA) was isolated from a fraction of the surviving population after each of the four rounds of infection as well as from the initial uninfected cells, and high-throughput sequencing of integrated sgRNA templates was performed to indirectly quantify the abundance of the associated mutants. We found that as our screen progressed, as would be expected for a library under strong selection, representation became biased toward a subset of enriched genes (see Fig. S2A in the supplemental material). Statistical analysis was performed using the STARS algorithm, which integrates data from independent guides targeting the same gene to identify the most enriched genotypes (26).

We identified 13 loci with statistically significant enrichment ( $P < 0.001$ ) in both libraries after 4 rounds of infection (Fig. 2A). Unexpectedly, given our results with purified toxin, more than half of the enriched loci encoded factors associated with sphingolipid biosynthesis, and many were closely connected to synthesis of Gb3, the




**FIG 1** Design of a CRISPR/Cas9 screen to identify host factors underlying susceptibility to EHEC infection. (A) Schematic of the infection and outgrowth process for an HT-29 CRISPR/Cas9 library undergoing multiple rounds of infection with  $\Delta\text{espZ}$  EHEC, which has an active T3SS and secretes Stx1 and Stx2. (B and C) Abundance of HT29 cells infected with the indicated strain relative to the abundance of mock-infected cells at day 1 (B) and day 5 (C) postinfection. Graphs display the mean and standard deviation (SD) from 3 independent experiments. \*\*,  $P < 0.01$ ; \*\*\*\*,  $P < 0.0001$ .

Stx receptor (Fig. 2B). For example, hits included the Golgi complex-localized enzymes A4GALT, which catalyzes the final step in Gb3 synthesis, B4GALT5, which catalyzes production of the A4GALT substrate lactosylceramide, and UGCG, which converts ceramide (a precursor for all glycosphingolipids) into glucosylceramide. Additional hits included the ER-localized SPTLC2, SPTSSA, and KDSR, all of which lie on the ceramide synthesis pathway, and ARF1, which indirectly regulates intracellular trafficking of glucosylceramide (27).

Enriched loci also included TM9SF2 and LAPTM4A, whose functions are largely unknown. Although both are members of larger gene families coding for structurally related proteins, only guide RNAs targeting these particular family members were found to be enriched, suggesting that they have specific functions conferring susceptibility to EHEC infection (Fig. S2B). Human TM9SF2 has been reported to be a Golgi complex-resident transmembrane protein required for the Golgi complex localization





**FIG 2** Mutations that disrupt sphingolipid biosynthesis and poorly characterized genes are enriched in the HT-29 CRISPR/Cas9 library following repeated infection with *espZ* EHEC. (A) Scatterplot of the statistical significance in each library (A and B) associated with the genes ranked in the top 5% by the STARS algorithm. Genes with a  $P$  value of  $\leq 0.001$  in both libraries (upper right quadrant) are named; genes within the ellipse all have  $P$  values of  $< 2.0 \times 10^{-6}$ . (B) Products of genes shown in panel A with  $P \leq 0.001$  in both libraries and schematic representation depicting the subcellular localization of enzymes (black) that contribute to sphingolipid biosynthesis. A subset of substrates/products is depicted in red. (C) Abundance of HT29 control and mutant cells infected with  $\Delta$ espZ EHEC relative to the abundance of mock-infected cells at day 5 postinfection. Graphs display the mean and SD from 3 independent experiments compared to HT-29 Cas9 (leftmost bar). \*,  $P < 0.05$ ; \*\*,  $P < 0.005$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$ .

of NDST1, a sulfotransferase (28). Its homologues in *Drosophila* (TM9SF2/4) and *Dictyostelium* (Phg1A/Phg1C) have been linked to innate immunity and membrane protein localization (29, 30). The LAPTM4A locus has been reported to encode a transmembrane protein localized to lysosomes and late endosomes. It has been linked to

intracellular transport of nucleosides, multidrug resistance, and maintenance of lysosomal integrity (31–34). In addition to the enrichment of guides targeting TM9SF2, LAPT4A, and genes related to sphingolipid biosynthesis, our analysis detected enrichment for guides targeting several genes associated with cancer and cell proliferation (MLLT3, TFAP4, ZNF217, and DUSP6) (35–38).

The prominence among our hits of Gb3-related genes was unanticipated, because our preliminary studies suggested that T3SS rather than Stx would exert the strongest selective pressure in our screen. T3SSs from several organisms have been hypothesized to associate with lipid rafts (39–41), transient membrane microdomains that typically are enriched in sphingolipids (including Gb3) (19); however, studies of T3SS activity and host membrane components have generally focused on the importance of cholesterol, and a role for Gb3 in EHEC pathogenesis beyond that of Stx receptor has not been reported. To more precisely define the contribution of screen hits to susceptibility to EHEC infection, we developed assays that enabled the effects of Stx and T3SS on HT-29 cells to be investigated independently. Host cells were infected in parallel with a *ΔespZ* mutant, a *ΔespZ ΔescN* mutant (which lacks an ATPase essential for T3SS activity), or a *ΔespZ Δstx1 Δstx2* mutant (*ΔΔstx* [a mutant that does not produce Stx1 or Stx2]) or were mock infected, and the number of host cells present after 1 or 5 days of infection was determined (Fig. S1B). These experiments revealed similar marked declines in abundance of HT-29 cells 1 day postinfection with the type 3-active *ΔespZ* or *ΔespZ ΔΔstx* EHEC (to <20% of that seen in mock-infected cells) (Fig. 1B); in contrast, the type 3-deficient but toxin-producing *ΔespZ ΔescN* mutant infection had no significant effect on host cell abundance at this time point (Fig. 1B). However, in the subsequent 4 days, there was a marked difference in growth between cells infected with the *ΔespZ* versus *ΔespZ ΔΔstx* strains. Population expansion of cells previously exposed to toxin (*ΔespZ* infection) was far slower than that of cells that were never exposed to the toxin (*ΔespZ ΔΔstx* infection) (Fig. 1C and Fig. S1B). The abundance of HT-29 cells infected with the *ΔespZ ΔescN* strain also differed significantly from that of mock-infected cells by day 5, likely further reflecting the consequence of toxin exposure at this time point. Collectively, these analyses demonstrate that the impact of T3SS is most clearly evident 1 day postinfection and can be differentiated from that of toxin via infection with the *ΔespZ ΔΔstx* strain. In contrast, the effects of Stx are delayed, become more apparent 5 days postinfection, and can be assayed in infection with the T3SS-deficient *ΔespZ ΔescN* strain. Given that our screen included multiple rounds of 5-day outgrowth following infection (during which effects of Stx could manifest), we conclude that the screen enriched for mutants resistant to Stx as well as T3SS.

For initial validation of our screen hits, mutants corresponding to selected enriched loci were constructed and verified by Sanger sequencing or Western blotting (Fig. S2C to E), and their abundance (relative to mock-infected cells) was assessed 5 days postinfection with *ΔespZ* EHEC. In comparison to the HT-29 Cas9 control strain, all but one mutant (ARF1) had significantly enhanced abundance at 5 days postinfection (Fig. 2C), suggesting that our selection and analysis yielded robust and reliable data regarding susceptibility to EHEC infection.

**Sphingolipid biosynthesis facilitates T3SS killing.** Because the hits predicted to be involved in cell proliferation (i.e., DUSP6, TFAP4, ZNF217, and MLLT3) were less likely to be involved in EHEC pathogenesis *per se*, we chose to focus further studies on a subset of the sphingolipid biosynthesis mutants and on mutants with mutations in the largely uncharacterized loci TM9SF2 and LAPT4A. In particular, we focused on factors mediating synthesis of glycosphingolipids, particularly A4GALT, which should only have impaired production of Gb3 and other globo-series glycosphingolipids (42), and UGCG, which is required for synthesis of all glycosphingolipids except galactosylceramines (43). ARF1 was also included, due to its contribution to intracellular trafficking of UGCG's product from the *cis*-medial Golgi complex to the *trans*-Golgi network, where B4GALT5 and A4GALT are found (27). To assess the bacterial factors underlying the enrichment of these loci, mutants were first infected with the *ΔespZ ΔΔstx* strain or


mock infected, and cell abundance was assessed 1 day following infection. Notably, all of the mutant cells displayed significantly elevated relative abundance compared to wt HT-29 cells (Fig. 3A). Coupled with our prior analyses of bacterial factors modulating host survival at this time point (Fig. 1B), these results suggest that these mutations confer resistance to  $\Delta espZ \Delta \Delta stx$  infection by protecting against the effects of EHEC's T3SS and thus that associated loci may play a role in the host cell response to T3SS. Of these factors, only ARF1 has previously been linked to T3SS-mediated processes; it is thought to facilitate insertion of the T3SS translocon during *Yersinia* infection (44) but has not been linked to T3SS activity in EHEC.

The first effector translocated by EHEC's T3SS, Tir, is essential for the activity of this secretion system. In the absence of Tir, translocation of additional effectors does not occur, nor does the characteristic cytoskeletal rearrangement and formation of membrane "pedestals" underneath adherent bacteria (5, 6). Tir translocation can be assessed using a Tir-CyA reporter fusion protein, followed by measurement of intracellular cAMP levels (45). We monitored translocation of this reporter, which is dependent on an intact T3SS, from WT EHEC into control HT-29 Cas9 cells and mutants that appeared resistant to the effects of T3SS. These experiments revealed significantly lower Tir translocation into all mutants than into control HT-29 cells, ranging from ~70% (A4GALT) down to ~10% (LAPTM4A) of wt levels (Fig. 3B). Consistent with this observation, immunofluorescence microscopy of wt and mutant HT-29 cells infected with wt EHEC revealed markedly fewer adherent bacteria and associated actin-rich pedestals. While EHEC formed pedestals on ~80% of infected wt HT-29 cells, pedestals were detected on only 18 to 35% of infected mutants tested, and fewer pedestals were generally observed per mutant cell (Fig. 3C, D, and E; see Fig. S3A in the supplemental material). Collectively, these results indicate that the mutations rendering HT-29 cells less susceptible to the cytotoxic effects of EHEC's T3SS all limit early steps in the T3SS effector translocation process, although they do not fully disrupt this process. These results also demonstrate that the mutants identified in our screen are protective against EHEC even when its T3SS activity has not been augmented by mutation of *espZ* ( $\Delta espZ$ ).

EHEC's T3SS machinery and associated effectors are similar to those of enteropathogenic *E. coli* (EPEC), a related pathogen that does not produce Shiga toxin but that also requires its T3SS to colonize and cause disease in the human intestine (46). We investigated whether the mutations that protect HT-29 cells from EHEC infection also render HT-29 less susceptible to EPEC. wt and mutant HT-29 cells were infected with an EPEC  $\Delta espZ$  mutant that, like its EHEC counterpart, is reported to have increased cytotoxicity relative to the wt strain (13, 47) (Fig. S3B). All 5 mutants tested exhibited increased survival compared to the wt cells at 1 day postinfection, and this increase was linked to the presence of a functional T3SS (Fig. S3C). Survival of the TM9SF2 and ARF1 mutants was particularly enhanced, with the number of infected cells nearing 50% of the mock-infected controls, compared to the ~5% observed with wt HT-29. Overall, our observations suggest that host glycosphingolipids modulate T3SS-mediated cytotoxicity for both pathogens, although pathogen reliance on particular sphingolipids is not necessarily conserved. For example, the absence of A4GALT had a dramatic effect on EHEC cytotoxicity, but only a modest influence on EPEC cytotoxicity. Additionally, our results suggest that TM9SF2 may play a conserved role in facilitating the activity of the EHEC and EPEC T3SSs.

Given previous reports that lipid rafts may promote T3SS activity and that Gb3 high-density association within lipid rafts is important for Stx binding (48), as well as our screen's identification of numerous sphingolipid-related loci, we hypothesized that TM9SF2 and LAPTM4A mutants might be less susceptible to EHEC infection due to alterations in lipid raft production or dynamics. To explore these possibilities, we compared the trafficking in control, TM9SF2, and LAPTM4A cells of a chimeric glycosylphosphatidylinositol-anchored green fluorescent protein construct (GPI-GFP), which is transported to the plasma membrane, where it becomes enriched in lipid rafts (49). Cell surface fluorescence was similarly homogenous in all three genetic backgrounds, and we could not detect consistent differences in steady-state plasma mem-





**FIG 3** Disruption of host sphingolipid biosynthesis genes and poorly characterized genes reduces the activity and cytotoxicity of EHEC's T3SS. (A) Abundance of control and mutant HT29 Cas9 cells infected with  $\Delta espZ \Delta \Delta stx1 \Delta stx2$  EHEC relative to the abundance of mock-infected cells at day 1 postinfection. Graphs display the mean and SD from 3 independent experiments. *P* values were obtained from one-way ANOVA with Dunnett's postcorrection (\*, *P* < 0.02; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001; \*\*\*\*, *P* < 0.0001). (B) Relative translocation of Tir-CyA from wt EHEC into HT-29 Cas9 control cells and the indicated HT-29 mutants based on cAMP levels. Translocation into HT-29 Cas9 control cells was set as 100%. Data reflect the mean and SD from 3 independent experiments. *P* values (\*\*\*\*, *P* < 0.0001) are based on one-way ANOVA with Dunnett's postcorrection. (C) Confocal microscopy of control and mutant HT-29 Cas9 cells infected for 6 h with GFP-EHEC and then stained for F-actin with Alexa 647-phalloidin (pink) and DAPI (blue [labels nuclei]). Merged images are shown. Focal colocalization of bacteria and actin reflects formation of actin pedestals. White boxes show enlarged images to highlight pedestals. (D) Percentage of the indicated host cells with actin pedestals 6 h after infection. Two hundred fifty cells were assessed for each host genotype. (E) Number of pedestals per host cell. Box plots show the range (minimum to maximum) of pedestal numbers. One hundred cells with AE lesions were counted per genotype. \*\*\*\*, *P* < 0.0001.

brane fluorescence between the 3 samples (Fig. S3D). To determine if the kinetics of trafficking and insertion might nevertheless differ between wt and mutant cells, we performed quantitative photobleaching. The rates of signal decay were similar for all 3 backgrounds, suggesting that bulk plasma membrane trafficking and lipid raft insertion are not grossly disrupted in TM9SF2 and LAPTM4A cells (Fig. S3E). Further studies will be needed to define the precise means by which these mutations, as well as others tested above, limit susceptibility to EHEC and EPEC T3SSs.


**LAPTM4A and TM9SF2 are required for Gb3 biosynthesis.** As noted above, the effects of Stx on HT-29 abundance were evident 5 days postinfection and could be clearly distinguished from those of EHEC's T3SS through infection with the Stx<sup>+</sup> T3SS-deficient  $\Delta$ escN mutant (Fig. 1C). Therefore, we also compared the abundance of wt HT-29 cells and several mutants from our panel after challenge with the  $\Delta$ escN strain. As anticipated, mutants lacking the sphingolipid biosynthesis factors A4GALT, UGCG, and SPTLC2 (all of which contribute to Gb3 production) were far less susceptible to  $\Delta$ escN mutant infection than wt HT-29 cells; at 5 days postinfection, the abundance of these mutants did not differ from that of mock-infected controls (Fig. 4A). Intriguingly, the TM9SF2 and LAPTM4A mutants were also significantly more abundant than wt cells by 5 days post- $\Delta$ escN mutant infection, suggesting that these factors not only contribute to resistance to T3SS-mediated cytotoxicity, but also could be host factors facilitating intoxication.

To begin to explore the means by which TM9SF2 and LAPTM4A mutations protect against Stx, we tested the capacity of mutants to bind to fluorescently tagged toxin. As controls, we also assayed A4GALT and UGCG mutants, which are known to be completely deficient in Gb3 production and hence cannot bind Stx. Flow cytometry analyses, which were performed both in HT-29 cells (Fig. 4B) and HeLa cells (see Fig. S4A in the supplemental material), revealed that there was a high (but not uniform) level of binding of Stx2 to both wt cell types. Notably, there was marked reduction in Stx binding in both the TM9SF2 and LAPTM4A mutant cells (Fig. 4B and Fig. S4A); these mutants bound equal or less toxin than the A4GALT and UGCG mutants. The residual binding observed in all genetic backgrounds may reflect nonspecific toxin adsorption or low-level genetic heterogeneity in the CRISPR/Cas9-mutagenized lines.

Similarly, fluorescence microscopy, which was performed using wt HeLa cells and their derivatives due to their favorable imaging characteristics, did not reveal Stx binding to any of the mutants, even when cells were permeabilized to enable binding to intracellular receptor (Fig. 4C and D). Thus, the TM9SF2 and LAPTM4A mutants' deficiencies in Stx binding do not appear to reflect impaired trafficking of Gb3 to the cell surface, but instead reflect defective synthesis and/or enhanced degradation of this glycosphingolipid.

To evaluate the specificity of the deficiency in the TM9SF2 and LAPTM4A HT-29 mutants, we used flow cytometry to measure their capacity to bind cholera toxin (CT), which interacts with the glycosphingolipid GM1 (Fig. 2B) (50). In contrast to the near ablation of Stx binding in these mutants, there was a comparatively modest reduction in the binding of fluorescently labeled CT to these cells compared to wt HT-29 cells and A4GALT mutant cells (which produce normal amounts of GM1) (Fig. S4B). As expected, the UGCG cells showed a far more marked decrease in binding to cholera toxin, since UGCG is required for synthesis of GM1 (43). Collectively, these observations suggest that the TM9SF2 and LAPTM4A mutants' deficiencies in Stx binding reflect relatively specific reductions in production of Gb3 or related globo-series glycosphingolipids, rather than deficiencies that consistently impair synthesis or trafficking to the cell membrane of multiple surface receptors. Coupled with our analysis of the set of mutants that display reduced sensitivity to T3SS-mediated cytotoxicity, these observations suggest that reduced production of Gb3 likely contributes to the TM9SF2 and LAPTM4A mutants' resistance to the effects of EHEC's T3SS as well as to Stx.


To gain greater insight into the mechanism by which TM9SF2 and LAPTM4A enable infection by EHEC, we determined their subcellular localization in HeLa cells via



**FIG 4** TM9SF2 and LAPT4A promote sensitivity to Stx. (A) Abundance of wt and mutant HT29 Cas9 cells infected with T3SS-deficient EHEC ( $\Delta espZ \Delta escN$ ) relative to the abundance of mock-infected cells at day 5 postinfection. *P* values are based on one-way ANOVA with Dunnett's posttest correction (\*\*\*\*, *P* < 0.0001). (B) Flow cytometry analysis of Stx2-Alexa 647 binding to wt and mutant HT-29 Cas9 cells. Histograms show the distribution of fluorescence intensity in the total cell population in the presence and absence of toxin. (C and D) Confocal microscopy of Stx2-Alexa 488 (green) binding to nonpermeabilized (C) and permeabilized (D) control and mutant HeLa Cas9 cells. Cells were also stained with DAPI and Alexa 568-phalloidin.

confocal microscopy. Consistent with previous reports (28), we found that TM9SF2 colocalized with GM130, a Golgi complex matrix protein (Fig. 5A). A subset of fluorescence emanated from nucleoli, potentially resulting from nonspecific primary antibody binding, although Stx has been reported to be actively transported into nucleoli (51). Unexpectedly, as prior studies localized LAPT4A to lysosomes (31–34), we found that a LAPT4A-GFP fusion protein localized to the Golgi complex, like TM9SF2 (Fig. 5A).

The subcellular distribution of TM9SF2 and LAPT4A raised the possibility that these proteins might enable EHEC infection by facilitating Gb3 biosynthesis, either by



**FIG 5** Subcellular localization of TM9SF2, LAPT4A, and A4GALT in wt and mutant HeLa cells. (A) Confocal immunofluorescence microscopy of HeLa cells stained with anti-TM9SF2 (green), anti-GM130 to label the Golgi complex (pink) and DAPI. For LAPT4A localization, HeLa cells were transfected with GFP-tagged LAPT4A, which was imaged directly after counterstaining as described above. (B) Confocal immunofluorescence microscopy of control and mutant HeLa Cas9 cells labeled with anti-A4GALT antibody (pink), anti-58K to label the Golgi complex (pink) and DAPI. GM130 and 58K stain similar populations of Golgi complex membranes and were used interchangeably to accommodate the primary antibodies of interest.

participating in Golgi complex localization of precursor substrates or enzymes specifically or by acting more generally as matrix proteins to ensure overall Golgi complex integrity. To investigate the former possibility, we immunolabeled the A4GALT enzyme in wt cells and in TM9SF2 and LAPT4A cells. A4GALT maintained proper Golgi complex localization in both mutant cell lines (Fig. 5B), suggesting that TM9SF2 and LAPT4A are not required either for the production or distribution of A4GALT. To investigate if TM9SF2 and LAPT4A might instead facilitate Gb3 trafficking by acting more generally in Golgi complex integrity, we performed qualitative and quantitative



image analysis of both *cis*-medial and *trans*-Golgi compartments. GM130 (a *cis*-medial Golgi marker) appeared morphologically normal in the mutant cells (see Fig. S5A in the supplemental material) and quantitative characterization of the *trans*-Golgi complex, where the final step in Gb3 biosynthesis is thought to occur, did not reveal differences in either the integrity (as measured by confocal z-stack nominal 2-dimensional area) or localization (as measured by nuclear centroid displacement) of this subcompartment (Fig. S5B and C). Further analyses will be required to identify the precise defect that leads to glycosphingolipid deficiency in these mutants.

## DISCUSSION

EHEC encodes two potent virulence factors that empower it to disrupt the colonic epithelium during infection: (i) its T3SS, which enables intimate attachment of bacteria as well as translocation of multiple effectors that disrupt epithelial cell processes, and (ii) Stx, a potent translation inhibitor that triggers multiple stress responses in cells within and outside the intestinal tract. These virulence factors were acquired by horizontal transmission in distinct steps in the pathogen's evolution (52) and are generally thought of as functionally independent. However, our CRISPR/Cas9-based screen for host mutants with reduced susceptibility to EHEC infection uncovered a remarkable overlap in host factors that mediate the response to these bacterial products. The screen for mutations enriched after infection with Stx<sup>+</sup> and T3SS<sup>+</sup> EHEC identified numerous loci known to be associated with sphingolipid and glycosphingolipid biosynthesis, in particular factors required for production of the Stx receptor Gb3, as well as two loci (TM9SF2 and LAPTM4A) with largely undefined cellular roles that were also required for toxin binding. Unexpectedly, mutants lacking these factors are also less susceptible to cytotoxicity associated with EHEC's T3SS. These mutations interfered with early events associated with T3SS and Stx pathogenicity, markedly reducing entry of T3SS effectors into host cells and binding of Stx. Although the means by which these host loci and the processes associated with them are exploited by EHEC are not fully understood, the convergence of Stx and T3SS onto overlapping targets raises intriguing possibilities for design of therapeutic agents countering EHEC infection.

Previous studies of Stx and EHEC T3SS have characterized some of the pathways through which these factors act upon host cells, such as the binding and retrograde transport that enable Stx to reach its intracellular target, the stress responses induced by Stx, the processes underlying formation of pedestals, and the targets and mechanisms of effectors (53–56). Notably, our findings suggest that disruption of only a subset of host genes provides protection against cytotoxicity when both virulence factors are present. Interestingly, we identified loci that influence early steps within virulence pathways, e.g., loci that are required for Stx binding to host cells or T3SS effector translocation rather than loci that mediate toxin trafficking (e.g., clathrin, dynamin, and SNX1/2) (18) or interact with translocated effectors (e.g., N-WASP, IRTKS, and IRSp53) (56–58). Such proximal factors have also been identified in other genome-wide CRISPR screens for host mutants resistant to cytotoxicity by other pathogens. For example, a *Yersinia* RNA interference (RNAi) screen and our *Vibrio parahaemolyticus* CRISPR screen yielded loci that reduced effector translocation (23, 44). For EHEC virulence factors, disrupting early steps in their interactions with host cells may be particularly protective because these virulence factors disrupt multiple cellular processes once internalized; for example, inactivation of the host response to a single T3SS effector may still leave cells vulnerable to the activity of other growth-interfering effectors.

Early steps in the interactions between host cells and EHEC's virulence factors were also likely identified in our screen because of the previously unrecognized overlap between host factors utilized by T3SS and Stx at the start of their encounters with epithelial cells. We found that mutants with disrupted synthesis of Gb3, which were expected to be resistant to Stx-mediated growth inhibition, also exhibited an unexpected reduction in their sensitivity to T3SS-mediated cytotoxicity that was associated with reduced translocation of Tir. A majority of these mutants also exhibited reduced



susceptibility to EPEC infection, suggesting that common host processes may mediate the actions of EHEC and EPEC's related T3SS.

Although many mutants identified by our screen share the characteristic of lacking Gb3, it is unlikely that this deficit is the sole factor underlying their resistance to T3SS. Mutants lacking A4GALT, UGCG, TM9SF2, and LAPT4A appear equally devoid of extracellular Gb3 in assays of Stx binding; however, they exhibit various degrees of resistance to  $\Delta$ espZ EHEC. T3SS resistance is also not fully correlated with the extent to which Tir translocation into these cells is reduced. These observations suggest that the reduction in Gb3 levels is associated with additional cellular changes (e.g., in overall sphingolipid homeostasis, membrane/lipid raft composition, or intracellular trafficking) that also modulate the host response to EHEC infection.

The means by which mutations in TM9SF2 and LAPT4A prevent accumulation of Gb3 remain to be determined. We found that both proteins are localized within the Golgi complex, raising the possibility that they modulate the activity, localization, or transport of glycosphingolipid biosynthetic factors, which also occurs within this organelle. TM9SF2 was previously found to regulate the localization of NDST1, a Golgi complex-localized enzyme that catalyzes N-sulfation of heparan sulfate, and to be required for accumulation of NDST1's reaction product (28). TM9SF2 and the associated heparan sulfate N-sulfation are important for host cell binding and entry by chikungunya virus (CHIKV) virus (28); however, the absence of other hits associated with heparan sulfate in our screen suggests that this phenotype is not related to our results. Minor abnormalities in several other glycosylation pathways were also associated with TM9SF2 disruption, but the underlying mechanism was not determined. We found that TM9SF2 is not required for correct localization or accumulation of A4GALT, suggesting that TM9SF2 may act prior to the terminal step of Gb3 synthesis. Similarly, LAPT4A mutation did not appear to modulate A4GALT production or localization. It is unclear why previous studies have observed LAPT4A in lysosomes and late endosomes rather than the Golgi complex localization that we detected; further studies will be needed to dissect the targeting and activity of LAPT4A and its relationship to production of Gb3. Protein annotation and studies in the mouse homologue (MTP) suggest LAPT4A may be involved in intracellular transport of nucleosides (59). Together with its Golgi complex localization shown herein, LAPT4A could be involved in transporting activated sugars to the Golgi complex lumen, to supply precursors for Gb3 biosynthesis.

Although EHEC is susceptible to common antibiotics, antibiotic treatment is generally contraindicated during EHEC infection, as antibiotics can increase production and release of Stx, leading to the development of HUS (60). A variety of alternative therapies have been proposed to counter the effects of toxin, including compounds that sequester or neutralize toxin, block its binding to host cells, or disrupt toxin internalization, processing, or intracellular activity (61). Their activity has largely been tested in toxin-treated cell lines; a few have also been studied in animal models, but not in the context of EHEC infection. Our results suggest that a subset of these compounds, namely, those that alter production of Gb3, may reduce pathogenesis associated with T3SS as well as Stx and thus may be particularly effective in countering EHEC infection. Further studies of these and related compounds may enable identification of agents that counter host susceptibility to translocation of EHEC's T3SS effectors, as well as to the effects of Stx, which could hold high therapeutic potential. Thus, our identification of host factors related to both T3SS and Stx susceptibility provides guidance in prioritizing the development of therapeutics aimed at countering EHEC pathogenesis.

## MATERIALS AND METHODS

**Bacterial strains, plasmids, and growth conditions.** All plasmids used in this study are listed in Table S3. Primers used in strain construction are shown in Table S1. Bacterial strains were cultured in LB medium or on LB agar plates at 37°C unless otherwise specified. Antibiotics and supplements were used at the following concentrations: carbenicillin, 50  $\mu$ g/ml; ampicillin, 100  $\mu$ g/ml; chloramphenicol, 20  $\mu$ g/ml; kanamycin, 50  $\mu$ g/ml; streptomycin, 200  $\mu$ g/ml; and IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside), 1  $\mu$ g/ml. The EHEC  $\Delta$ espZ deletion mutant was constructed by allelic exchange using a derivative of the suicide vector pDM4 that included *espZ*-flanking sequences (62). Deletion of *stx1*, *stx2*, and *escN* was performed using lambda red-mediated recombination (63).

**Eukaryotic cell lines and growth conditions.** HT-29, HeLa, and 293T cells and their derivatives were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. Cells were grown at 37°C with 5% CO<sub>2</sub> and routinely passaged at 70 to 80% confluence; medium was replenished every 2 to 3 days.

**Positive selection screen using the HT-29 CRISPR Avana libraries.** The HT-29 libraries were constructed as described previously (23) using the Avana sgRNA library, which contains four sgRNAs targeting each of the human protein-coding genes (26). For each library, two sets of 7 T225 flasks were seeded with  $12.5 \times 10^6$  cells per flask and then incubated for 48 h. At the time of the screen, there were  $175 \times 10^6$  cells per experimental condition, corresponding to  $\sim 2,000\times$  coverage per perturbation. Cells were at  $\sim 70\%$  confluence at the time of infection. One set of flasks served as an uninfected control; the second was infected with the EHEC  $\Delta$ espZ strain. Cells were harvested from the control at the time of infection.

For infection, the  $\Delta$ espZ strain was grown overnight statically in LB medium to an optical density at 600 nm (OD<sub>600</sub>) of 0.6 and then centrifuged and resuspended at an OD<sub>600</sub> of 0.5 in DMEM. HT-29 cells were infected with EHEC  $\Delta$ espZ at an MOI of 100 and incubated under standard culture conditions for 6 h, with a medium change at 3 h postinfection to remove nonadherent bacteria and prevent medium acidification. At 6 h postinfection, cells were washed 3 times with  $1\times$  Dulbecco's phosphate-buffered saline (DPBS) to remove nonadherent bacteria and then replenished with fresh medium supplemented with  $1\times$  antibiotic-antimycotic solution (ABAM) (Gibco medium containing 100  $\mu$ g/ml streptomycin) and gentamicin 100  $\mu$ g/ml ("stop medium"). After overnight incubation, fresh stop medium was added to each flask. Flasks were monitored daily by inverted light microscopy to monitor the recovery of survivor cells. Upon reaching 70% confluence, the cells were trypsinized, pooled, and reseeded for the next round of infection, always keeping a minimum number of  $80 \times 10^6$  cells to maintain a coverage of at least  $1,000\times$ . The infection and selection procedure was repeated for the second, third, and fourth rounds of infection. Additionally, a subset of cells from each population were used for preparation of genomic DNA.

**Genomic DNA preparation, sequencing, and STARS analyses of screen results.** Genomic DNA (gDNA) was extracted from  $100 \times 10^6$  input cells (uninfected) and after each round of infection with the EHEC  $\Delta$ espZ strain (rounds 1, 2, 3 and 4) using the Blood and Cell Culture DNA Maxi kit from Qiagen. The gDNA was subjected to PCR to amplify guide RNA sequences as previously described (26). The read counts were first normalized to reads per million under each condition by the following formula: reads per sgRNA/total reads per condition  $\times 10^6$ . Reads per million were then log<sub>2</sub> transformed by first adding 1 to all values, in order to take the log of sgRNAs with zero reads. For analyses, the log<sub>2</sub> fold change of each sgRNA was determined relative to the input sample for each biological replicate (see Table S2 in the supplemental material). The STARS algorithm for CRISPR-based genetic perturbation screens was used to evaluate the rank and statistical significance of the candidate genes as described (26).

**Construction of HT-29 Cas9 and HeLa cells with targeted gene disruptions.** The sgRNA sequences used for construction of HT-29 Cas9 mutant cells are shown in Table S3 in the supplemental material. All sgRNA oligonucleotide sequences were obtained from Integrated DNA Technologies, Inc., and cloned into the pLentiGuide-Puro plasmid as previously described (23). Briefly, 5  $\mu$ g of plasmid pLentiGuide-Puro was digested with BsmBI (Fermentas) and purified using the QIAquick gel extraction kit. Each pair of oligonucleotides was annealed and phosphorylated with T4 PNK (NEB) in the presence of  $10\times$  T4 DNA ligase buffer in a thermocycler with the following parameters: (i) incubation for 30 min at 37°C, (ii) incubation at 95°C for 5 min with a ramp down to 25°C at 5°C per min. Oligonucleotides were then diluted 1:200, and 1  $\mu$ l of the diluted oligonucleotide mixture was ligated with 50 ng of BsmBI-digested plasmid. Ligations were transformed into STBL3 bacteria, and transformed clones were checked by PCR and DNA sequencing. sgRNAs cloned into pLentiGuide-Puro were transduced into HT-29 Cas9 cells as described below, and after 10 days of selection with puromycin (1  $\mu$ g/ml), the extent of disruption of the targeted gene was analyzed by immunoblotting for the corresponding gene product or Sanger sequencing (Fig. S2C).

**Lentivirus preparation and transductions.** Lentiviral transductions were performed as previously described (23). Briefly, all lentiviruses were made by transfecting 293T cells using TransIT-LT1 transfection reagent, the lentiviral packaging plasmids psPAX2 and pCMV-VSVG, and the corresponding cargo plasmid according to the manufacturer's protocol. Forty-eight hours following transfection, 293T culture supernatant was harvested, filtered through a 0.22- $\mu$ m-pore filter, and added to target HT-29 or HeLa cells grown to 70 to 80% confluence in 6-well plates; a second virus supernatant was harvested 72 h after transfection and added to target cells. Spin infection was performed by adding 8  $\mu$ g/ml Polybrene and spinning the 6-well plates at  $1,600 \times g$  for 2 h at 30°C; HT-29 cells were then returned to 37°C. Puromycin selection for positive transductants was initiated the following day. For transduction of HeLa cells, spin infection was not performed.

**Cell survival assays.** For cell survival assays,  $5 \times 10^5$  HT-29 cells were seeded into 6-well plates and grown for 48 h in DMEM supplemented with 10% FBS. EHEC (or EPEC) strains for infections were prepared as for the library infections described above. HT-29 cells were infected at an MOI of 100 (or with uninoculated media in the case of mock infection), with medium changes and infection termination as for library infection. Mock-infected cells were fed but not passaged during the outgrowth period. Following infection and outgrowth for 1 or 5 days, cells were quantified by trypan blue (0.4%) exclusion using a Countess II automated cell counter (Thermo Fisher Scientific). Cell survival after EPEC infection was measured 4 h postinfection.

**Stx cytotoxicity assay and measurement of Stx released during infection.** HT-29 cells were seeded at  $1 \times 10^6$  cells/well the day before the assay. Cell monolayers were then exposed to a range of concentrations of pure Stx1 or Stx2 holotoxins for 6 h. Cell survival was measured by trypan blue exclusion as described above, and then the percentage of survival was calculated in comparison to HT-29

controls that did not receive toxin treatment. Stx released during infection of HT-29 cells at 3 and 6 h was measured by enzyme-linked immunosorbent assay (ELISA), as described previously (64).

**Tir translocation assays.** The Tir translocation assay was performed as previously described (45). Briefly, HT-29 cells were plated at  $1 \times 10^5$  cells/well in 96 wells and assayed at confluence. EHEC strains harboring a Tir-CyaA fusion or CyaA vector control were grown in LB overnight and then diluted 1:100 in DMEM and grown to an  $OD_{600}$  of 0.6 with shaking at 37°C. Cells were infected at an MOI of 100:1 for 90 min; cAMP was measured by ELISA using the Biotrack cAMP kit (Amersham) according to the manufacturer's instructions.

**Immunoblot analyses.** Mammalian cell lysates were prepared with radioimmunoprecipitation assay (RIPA) buffer, and protein concentrations were determined using the bicinchoninic acid (BCA) protein assay. Ten micrograms of protein lysate was mixed with NuPAGE LDS sample buffer (Invitrogen) with 50 mM dithiothreitol (DTT), separated by NuPAGE bis-Tris gel electrophoresis, and transferred to nitrocellulose membranes. The antibodies and concentrations used are listed in Table S4 in the supplemental material. Blots were developed with the SuperSignal West Pico ECL (enhanced chemiluminescence) kit, and imaging was performed on the Chemidoc Touch imaging system (Bio-Rad).

**Immunofluorescence.** HT-29 cells or HeLa cells were seeded in 12-well plates on 18-mm glass coverslips or 4-well chambers (Mat-TEK). Cells were fixed with 2% paraformaldehyde (PFA) for 20 min at room temperature, washed with  $1 \times$  PBS 3 times, and then permeabilized with 0.1% Triton X-100 in PBS for 30 min (except for cells stained for TM9SF2, which were subjected to combined fixation and permeabilization in ice-cold methanol for 10 min). Cells were blocked in 5% normal goat serum in PBS (blocking buffer) for 1 h, followed by overnight incubation with primary antibodies (Table S4) at 4°C. Cells were then washed 3 times with PBS followed by incubation with fluorescently labeled secondary antibody for 1 h at room temperature. Cells were counterstained with Alexa 568-phalloidin and DAPI (4',6-diamidino-2-phenylindole) for actin cytoskeleton and nuclei, respectively. For extracellular binding of Alexa 488-tagged Stx, cells were not permeabilized; for intracellular binding, cells were permeabilized and stained as described above.

**LAPTM4A subcellular localization.** HeLa Cas9 cells were plated on coverslips and transfected with LAPTM4A-GFP (Origene) per the manufacturer's protocol (Mirus). Twenty-four hours later, cells were processed for immunofluorescence as described above. GFP was imaged directly without additional signal amplification.

**FAS.** Fluorescent actin staining (FAS) assays were performed as described previously (65), with minor modifications. Briefly, HT-29 cells were seeded at  $1 \times 10^6$  cells/well in 4-well chambers in DMEM plus FBS. Three days after confluence, cells were infected with EHEC strains expressing GFP at an MOI of 100 for 6 h, with a medium change after 3 h. After infection, cells were washed three times with PBS, fixed with 2% PFA, and permeabilized with 0.2% Triton X-100. Cells were then stained with Alexa 633-phalloidin and DAPI for visualization of actin cytoskeleton and cell nuclei. Slides were mounted using Prolong Diamond antifade and analyzed by confocal microscopy. The experiment was repeated at least 3 times, and 250 cells were counted in total. The percentage of infected cells was determined by analyzing at least 20 random fields across different experiments; numbers of pedestals were determined by counting AE lesions in 100 infected cells. All comparisons were relative to HT-29 cells.

**Lipid raft assay.** For imaging of GFP-GPI, the indicated cells were split into 12-well glass bottom plates (MatTek). One day later, cells were transfected with GFP-GPI using TransIT-LT1 reagent following the manufacturer's recommended protocol (Mirus). Twenty-four hours later, cells were washed and then imaged in FluoroBrite-DMEM (Invitrogen), with live fields of single confocal slices of cell bottoms taken for 1 min using 1-s exposures at 75% laser power. Region of interest (ROI) mean intensities (with ROI drawn to avoid overlapping cell protrusions and saturated pixels) were calculated for each frame using the Plot Z-axis profile function in ImageJ. More than 20 cells and at least 20 movies were analyzed for each condition. Results are expressed as mean  $\pm$  standard error of the mean (SEM).

**Golgi complex morphological analyses.** Golgi complex integrity was assayed by calculation of the mean distance between the manually defined weighted centroid of nucleus (as defined by DAPI staining) and *trans*-Golgi network (as defined by TGN46 staining) and from the 2-dimensional area of manually defined ROI of maximum-intensity projection of individual confocal slices of TGN46 staining. At least 20 cells were analyzed for each condition. Results are expressed as mean  $\pm$  SEM.

**Shiga toxin labeling and flow cytometry (FACS).** Shiga toxins 1 and 2 (holotoxins) were obtained from Tufts Medical Center; cholera toxin was purchased from Sigma. All toxins were diluted in PBS and labeled with an Alexa 488 or Alexa 647 microlabeling kit (Invitrogen) according to the manufacturer's instructions. For fluorescence-activated cell sorter (FACS) analysis of Stx binding, HT-29 cells were seeded at  $5 \times 10^5$  cells/well in 6-well plates, while HeLa cells were seeded at  $2.5 \times 10^5$  cells/well and then incubated for 24 h. Cell monolayers were washed 3 times with Earle's balanced salt solution (EBSS), trypsinized, resuspended in PBS with labeled Stx (10 nM) or CT (1 nM), and incubated on ice for 30 min. Cells were then centrifuged, resuspended in FACS buffer (DPBS plus 10% FBS), and analyzed by flow cytometry.

**Statistical methods.** Statistical analyses were carried out using a one-way analysis of variance (ANOVA) with Dunnett's postcorrection on GraphPad Prism5.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.01003-18>.

**FIG S1**, PDF file, 0.5 MB.

**FIG S2**, PDF file, 5.4 MB.

**FIG S3**, PDF file, 7.6 MB.

**FIG S4**, PDF file, 0.2 MB.

**FIG S5**, PDF file, 3.6 MB.

**TABLE S1**, PDF file, 0.1 MB.

**TABLE S2**, PDF file, 0.3 MB.

**TABLE S3**, PDF file, 0.1 MB.

**TABLE S4**, PDF file, 0.1 MB.

## ACKNOWLEDGMENTS

We gratefully acknowledge James Kaper (University of Maryland) for providing EPEC strains and the Tir-CyaA plasmid, to Yusuke Maeda (Osaka University) for providing anti-TM9SF2 antibody, and to Peter Howley for HeLa Cas9 parental cells. We thank Waldor lab members for helpful discussion about this project.

This work was supported by HHMI and R01 AI-042347 to M.K.W. B.S. was supported by a National Sciences and Engineering Research Council of Canada (NSERC) PGS-D award (487259), and J.E.L. was supported by the NIH under NRSA T32AI007061 from the NIAID. C.J.B. is supported by grants FONDECYT 11160901 and REDI170269, and is a Howard Hughes Medical Institute-Gulbenkian International Research Scholar.

## ADDENDUM IN PROOF

In an independent CRISPR screen, Songhai Tian and Min Dong also discovered that LAPTM4A and TM9SF2 are required for Gb3 synthesis (S. Tian, K. Muneeruddin, M. Y. Choi, L. Tao, R. H. Bhuiyan, Y. Ohmi, K. Furukawa, K. Furukawa, S. A. Shaffer, R. M. Adams, and M. Dong, submitted for publication).

## REFERENCES

- Kaper JB, O'Brien ADO. 2014. Overview and historical perspectives. *Microbiol Spectr* 2:1–9. <https://doi.org/10.1128/microbiolspec.EHEC-0028-2014>.
- Jarvis KG, Girón JA, Jerse AE, McDaniel TK, Donnenberg MS, Kaper JB. 1995. Enteropathogenic *Escherichia coli* contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. *Proc Natl Acad Sci U S A* 92: 7996–8000. <https://doi.org/10.1073/pnas.92.17.7996>.
- Dettmar AK, Binder E, Greiner FR, Liebau MC, Kurschat CE, Jungraithmayr TC, Saleem MA, Schmitt CP, Feifel E, Orth-Höller D, Kemper MJ, Pepys M, Würzner R, Oh J. 2014. Protection of human podocytes from Shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component. *Infect Immun* 82: 1872–1879. <https://doi.org/10.1128/IAI.01591-14>.
- Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, O'Brien AD. 1986. Two toxin-converting phages from *Escherichia coli* O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. *Infect Immun* 53:135–140.
- Kenny B, DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB. 1997. Enteropathogenic *E. coli* (EPEC) transfers its receptor for intimate adherence into mammalian cells. *Cell* 91:511–520. [https://doi.org/10.1016/S0092-8674\(00\)80437-7](https://doi.org/10.1016/S0092-8674(00)80437-7).
- Jerse AE, Yu J, Tall BD, Kaper JB. 1990. A genetic locus of enteropathogenic *Escherichia coli* necessary for the production of attaching and effacing lesions on tissue culture cells. *Proc Natl Acad Sci U S A* 87: 7839–7843. <https://doi.org/10.1073/pnas.87.20.7839>.
- Tzipori S, Gunzer F, Donnenberg MS, de Montigny L, Kaper JB, Donohue-Rolfe A. 1995. The role of the *eaeA* gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic *Escherichia coli* infection. *Infect Immun* 63:3621–3627.
- Ritchie JM, Thorpe CM, Rogers AB, Waldor MK. 2003. Critical roles for *stx2*, *eae*, and *tir* in enterohemorrhagic *Escherichia coli*-induced diarrhea and intestinal inflammation in infant rabbits. *Infect Immun* 71: 7129–7139. <https://doi.org/10.1128/IAI.71.12.7129-7139.2003>.
- Tobe T, Beatson SA, Taniguchi H, Abe H, Bailey CM, Fivian A, Younis R, Matthews S, Marches O, Frankel G, Hayashi T, Pallen MJ. 2006. An extensive repertoire of type III secretion effectors in *Escherichia coli* O157 and the role of lambdoid phages in their dissemination. *Proc Natl Acad Sci U S A* 103:14941–14946. <https://doi.org/10.1073/pnas.0604891103>.
- Stevens MP, Frankel GM. 2014. The locus of enterocyte effacement and associated virulence factors of enterohemorrhagic *Escherichia coli*. *Microbiol Spectr* 2:EHEC-0007-2013. <https://doi.org/10.1128/microbiolspec.EHEC-0007-2013>.
- Santos AS, Finlay BB. 2015. Bringing down the host: enteropathogenic and enterohaemorrhagic *Escherichia coli* effector-mediated subversion of host innate immune pathways. *Cell Microbiol* 17:318–332. <https://doi.org/10.1111/cmi.12412>.
- Mills E, Baruch K, Charpentier X, Kobi S, Rosenshine I. 2008. Real-time analysis of effector translocation by the type III secretion system of enteropathogenic *Escherichia coli*. *Cell Host Microbe* 3:104–113. <https://doi.org/10.1016/j.chom.2007.11.007>.
- Berger CN, Crepin VF, Baruch K, Mousnier A, Rosenshine I, Frankel G. 2012. EspZ of enteropathogenic and enterohemorrhagic *Escherichia coli* regulates type III secretion system protein translocation. *mBio* 3:e00137–12. <https://doi.org/10.1128/mBio.00317-12>.
- Steil D, Schepers CL, Pohlentz G, Legros N, Runde J, Humpf HU, Karch H, Müthing J. 2015. Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment. *J Lipid Res* 56:2322–2336. <https://doi.org/10.1194/jlr.M063040>.
- Zumbrun SD, Hanson L, Sinclair JF, Freedy J, Melton-Celsa AR, Rodriguez-Canales J, Hanson JC, O'Brien AD. 2010. Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. *Infect Immun* 78:4488–4499. <https://doi.org/10.1128/IAI.00620-10>.
- Békássy ZD, Calderon Toledo C, Leoj G, Kristoffersson A, Leopold SR, Perez MT, Karpman D. 2011. Intestinal damage in enterohemorrhagic *Escherichia coli* infection. *Pediatr Nephrol* 26:2059–2071. <https://doi.org/10.1007/s00467-010-1616-9>.
- Stone SM, Thorpe CM, Ahluwalia A, Rogers AB, Obata F, Vozenilek A, Kolling GL, Kane AV, Magun BE, Jandhyala DM. 2012. Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor ima-



- tinib. *Front Cell Infect Microbiol* 2:135. <https://doi.org/10.3389/fcimb.2012.00135>.
18. Johannes L, Römer W. 2010. Shiga toxins—from cell biology to biomedical applications. *Nat Rev Microbiol* 8:105–116. <https://doi.org/10.1038/nrmicro2279>.
  19. Kouzel IU, Pohlentz G, Storck W, Radamm L, Hoffmann P, Bielaszewska M, Bauwens A, Cichon C, Schmidt MA, Mormann M, Karch H, Müthing J. 2013. Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells. *J Lipid Res* 54:692–710. <https://doi.org/10.1194/jlr.M031781>.
  20. Tesh VL. 2013. Activation of cell stress response pathways by Shiga toxins. *Cell Microbiol* 14:1–9. <https://doi.org/10.1111/j.1462-5822.2011.01684.x>.
  21. Smith WE, Kane AV, Campbell ST, Acheson DW, Cochran BH, Thorpe CM. 2003. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. *Infect Immun* 71:1497–1504. <https://doi.org/10.1128/IAI.71.3.1497-1504.2003>.
  22. Jandhyala DM, Ahluwalia A, Schimmel JJ, Rogers AB, Leong JM, Thorpe CM. 2016. Activation of the classical mitogen-activated protein kinases is part of the Shiga toxin-induced ribotoxic stress response and may contribute to Shiga toxin-induced inflammation. *Infect Immun* 84:138–148. <https://doi.org/10.1128/IAI.00977-15>.
  23. Blondel CJ, Park JS, Hubbard TP, Pacheco AR, Kuehl CJ, Walsh MJ, Davis BM, Gewurz BE, Doench JG, Waldor MK. 2016. CRISPR/Cas9 screens reveal requirements for host cell sulfation and fucosylation in bacterial type III secretion system-mediated cytotoxicity. *Cell Host Microbe* 20:226–237. <https://doi.org/10.1016/j.chom.2016.06.010>.
  24. Tao L, Zhang J, Meraner P, Tovaglieri A, Wu X, Gerhard R, Zhang X, Stallcup WB, Miao J, He X, Hurdle JG, Breault DT, Brass AL, Dong M. 2016. Frizzled proteins are colonic epithelial receptors for *C. difficile* toxin B. *Nature* 538:350–355. <https://doi.org/10.1038/nature19799>.
  25. Savidis G, McDougall WM, Meraner P, Ferreira JM, Portmann JM, Trincucci G, John SP, Aker AM, Renzette N, Robbins DR, Guo Z, Green S, Kowalik TF, Brass AL. 2016. Identification of Zika virus and dengue virus dependency factors using functional genomics. *Cell Rep* 16:232–246. <https://doi.org/10.1016/j.celrep.2016.06.028>.
  26. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE. 2016. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol* 34:184–191. <https://doi.org/10.1038/nbt.3437>.
  27. Yamaji T, Hanada K. 2015. Sphingolipid metabolism and interorganellar transport: localization of sphingolipid enzymes and lipid transfer proteins. *Traffic* 16:101–122. <https://doi.org/10.1111/tra.12239>.
  28. Tanaka A, Tumkosit U, Nakamura S, Motooka D, Kishishita N, Priengprom T, Sa-Ngasang A, Kinoshita T, Takeda N, Maeda Y. 2017. Genome-wide screening uncovers the significance of N-sulfation of heparan sulfate as a host cell factor for chikungunya virus infection. *J Virol* 91:e00432-17. <https://doi.org/10.1128/JVI.00432-17>.
  29. Perrin J, Mortier M, Jacomini AC, Viargues P, Thevenon D, Fauvarque MO. 2015. The nonaspanins TM9SF2 and TM9SF4 regulate the plasma membrane localization and signalling activity of the peptidoglycan recognition protein PGRP-LC in *Drosophila*. *J Innate Immun* 7:37–46. <https://doi.org/10.1159/000365112>.
  30. Perrin J, Le Coadic M, Vernay A, Dias M, Gopaladas N, Ouertatani-Sakouhi H, Cosson P. 2015. TM9 family proteins control surface targeting of glycine-rich transmembrane domains. *J Cell Sci* 128:2269–2277. <https://doi.org/10.1242/jcs.164848>.
  31. Hogue DL, Nash C, Ling V, Hobman TC. 2002. Lysosome-associated protein transmembrane 4 alpha (LAPTM4 alpha) requires two tandemly arranged tyrosine-based signals for sorting to lysosomes. *Biochem J* 365:721–730. <https://doi.org/10.1042/BJ20020205>.
  32. Grabner A, Brast S, Susic S, Bierer S, Hirsch B, Pavenstädt H, Sitte HH, Schlatter E, Ciarimboli G. 2011. LAPTM4A interacts with hOCT2 and regulates its endocytotic recruitment. *Cell Mol Life Sci* 68:4079–4090. <https://doi.org/10.1007/s00018-011-0694-6>.
  33. Hogue DL, Kerby L, Ling V. 1999. A mammalian lysosomal membrane protein confers multidrug resistance upon expression in *Saccharomyces cerevisiae*. *J Biol Chem* 274:12877–12882. <https://doi.org/10.1074/jbc.274.18.12877>.
  34. Milkereit R, Rotin D. 2011. A role for the ubiquitin ligase Nedd4 in membrane sorting of LAPTM4 proteins. *PLoS One* 6:e27478. <https://doi.org/10.1371/journal.pone.0027478>.
  35. Fleischmann KK, Pagel P, Schmid I, Roscher AA. 2014. RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. *Mol Cancer* 13:27. <https://doi.org/10.1186/1476-4598-13-27>.
  36. Wei J, Yang P, Zhang T, Chen Z, Chen W, Wanglin L, He F, Wei F, Huang D, Zhong J, Yang Z, Chen H, Hu H, Zeng S, Sun Z, Cao J. 2017. Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients. *Exp Ther Med* 14:3057–3061. <https://doi.org/10.3892/etm.2017.4875>.
  37. Thollet A, Vendrell JA, Payen L, Ghayad SE, Ben Larbi S, Grisard E, Collins C, Villedieu M, Cohen PA. 2010. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. *Mol Cancer* 9:291. <https://doi.org/10.1186/1476-4598-9-291>.
  38. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. 2003. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. *Am J Pathol* 162:1807–1815. [https://doi.org/10.1016/S0002-9440\(10\)64315-5](https://doi.org/10.1016/S0002-9440(10)64315-5).
  39. Hayward RD, Cain RJ, McGhie EJ, Phillips N, Garner MJ, Koronakis V. 2005. Cholesterol binding by the bacterial type III translocon is essential for virulence effector delivery into mammalian cells. *Mol Microbiol* 56:590–603. <https://doi.org/10.1111/j.1365-2958.2005.04568.x>.
  40. Lafont F, Tran Van Nhieu G, Hanada K, Sansonetti P, Van Der Goot FG. 2002. Initial steps of *Shigella* infection depend on the cholesterol/sphingolipid raft-mediated CD44 ± IpaB interaction. *EMBO J* 21:4449–4457. <https://doi.org/10.1093/emboj/cdf457>.
  41. van der Goot FG, Tran van Nhieu G, Allaoui A, Sansonetti P, Lafont F. 2004. Rafts can trigger contact-mediated secretion of bacterial effectors via a lipid-based mechanism. *J Biol Chem* 279:47792–47798. <https://doi.org/10.1074/jbc.M406824200>.
  42. Kojima Y, Fukumoto S, Furukawa K, Okajima T, Wiels J, Yokoyama K, Suzuki Y, Urano T, Ohta M, Furukawa K. 2000. Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids. *J Biol Chem* 275:15152–15156. <https://doi.org/10.1074/jbc.M909620199>.
  43. Yamaji T, Hanada K. 2014. Establishment of HeLa cell mutants deficient in sphingolipid-related genes using TALENs. *PLoS One* 9:e88124. <https://doi.org/10.1371/journal.pone.0088124>.
  44. Sheahan KL, Isberg RR. 2015. Identification of mammalian proteins that collaborate with type III secretion system function: involvement of a chemokine receptor in supporting translocon activity. *mBio* 6:e02023-14. <https://doi.org/10.1128/mBio.02023-14>.
  45. Crawford JA, Kaper JB. 2002. The N-terminus of enteropathogenic *Escherichia coli* (EPEC) Tir mediates transport across bacterial and eukaryotic cell membranes. *Mol Microbiol* 46:855–868. <https://doi.org/10.1046/j.1365-2958.2002.03214.x>.
  46. Kaper JB, Nataro JP, Mobley HLT. 2004. Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2:123–140. <https://doi.org/10.1038/nrmicro818>.
  47. Kanack KJ, Crawford JA, Tatsuno I, Karmali MA, Kaper JB. 2005. SepZ/EspZ is secreted and translocated into HeLa cells by the enteropathogenic *Escherichia coli* type III secretion system. *Infect Immun* 73:4327–4337. <https://doi.org/10.1128/IAI.73.7.4327-4337.2005>.
  48. Hanashima T, Miyake M, Yahiro K, Iwamaru Y, Ando A, Morinaga N, Noda M. 2008. Effect of Gb3 in lipid rafts in resistance to Shiga-like toxin of mutant Vero cells. *Microb Pathog* 45:124–133. <https://doi.org/10.1016/j.micpath.2008.04.004>.
  49. Legler DF, Doucey MA, Schneider P, Chapatte L, Bender FC, Bron C. 2005. Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. *FASEB J* 19:73–75. <https://doi.org/10.1096/fj.03-1338fje>.
  50. Saslowsky DE, te Welscher YM, Chinnappen DJ, Wagner JS, Wan J, Kern E, Lencer WI. 2013. Ganglioside GM1-mediated transcytosis of cholera toxin bypasses the retrograde pathway and depends on the structure of the ceramide domain. *J Biol Chem* 288:25804–25809. <https://doi.org/10.1074/jbc.M113.474957>.
  51. Baibakov B, Murtazina R, Elowsky C, Giardiello FM, Kovbasnjuk O. 2010. Shiga toxin is transported into the nucleoli of intestinal epithelial cells via a carrier-dependent process. *Toxins* 2:1318–1335. <https://doi.org/10.3390/toxins2061318>.
  52. Sadiq SM, Hazen TH, Rasko DA, Eppinger M. 2014. EHEC genomics: past, present, and future. *Microbiol Spectr* 2:EHEC-0020-2013. <https://doi.org/10.1128/microbiolspec.EHEC-0020-2013>.
  53. Sandvig K, van Deurs B. 1996. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. *Physiol Rev* 76:949–966. <https://doi.org/10.1152/physrev.1996.76.4.949>.
  54. Lee SY, Lee MS, Cherla RP, Tesh VL. 2008. Shiga toxin 1 induces apoptosis



- through the endoplasmic reticulum stress response in human monocytic cells. *Cell Microbiol* 10:770–780. <https://doi.org/10.1111/j.1462-5822.2007.01083.x>.
55. Cantarelli VV, Kodama T, Nijstad N, Abolghait SK, Nada S, Okada M, Iida T, Honda T. 2007. Tyrosine phosphorylation controls cortactin binding to two enterohaemorrhagic *Escherichia coli* effectors: Tir and EspFu/TccP. *Cell Microbiol* 9:1782–1795. <https://doi.org/10.1111/j.1462-5822.2007.00913.x>.
  56. Vingadassalom D, Kazlauskas A, Skehan B, Cheng HC, Magoun L, Robbins D, Rosen MK, Saksela K, Leong JM. 2009. Insulin receptor tyrosine kinase substrate links the *E. coli* O157:H7 actin assembly effectors Tir and EspF(U) during pedestal formation. *Proc Natl Acad Sci U S A* 106:6754–6759. <https://doi.org/10.1073/pnas.0809131106>.
  57. Campellone KG, Cheng HC, Robbins D, Siripala AD, McGhie EJ, Hayward RD, Welch MD, Rosen MK, Koronakis V, Leong JM. 2008. Repetitive N-WASP-binding elements of the enterohemorrhagic *Escherichia coli* effector EspF(U) synergistically activate actin assembly. *PLoS Pathog* 4:e1000191. <https://doi.org/10.1371/journal.ppat.1000191>.
  58. Weiss SM, Ladwein M, Schmidt D, Ehinger J, Lommel S, Städing K, Beutling U, Disanza A, Frank R, Jänsch L, Scita G, Gunzer F, Rottner K, Stradal TE. 2009. IRSp53 links the enterohemorrhagic *E. coli* effectors Tir and EspFU for actin pedestal formation. *Cell Host Microbe* 5:244–258. <https://doi.org/10.1016/j.chom.2009.02.003>.
  59. Cabrita MA, Hobman TC, Hogue DL, King KM, Cass CE. 1999. Mouse transporter protein, a membrane protein that regulates cellular multi-drug resistance, is localized to lysosomes. *Cancer Res* 59:4890–4897.
  60. Pacheco AR, Sperandio V. 2012. Shiga toxin in enterohemorrhagic *E. coli*: regulation and novel anti-virulence strategies. *Front Cell Infect Microbiol* 2:81. <https://doi.org/10.3389/fcimb.2012.00081>.
  61. Kavaliauskiene S, Dyve Lingelem AB, Skotland T, Sandvig K. 2017. Protection against Shiga toxins. *Toxins* 9:1–25. <https://doi.org/10.3390/toxins9020044>.
  62. Zhou X, Gewurz BE, Ritchie JM, Takasaki K, Greenfield H, Kieff E, Davis BM, Waldor MK. 2013. A *Vibrio parahaemolyticus* T3SS effector mediates pathogenesis by independently enabling intestinal colonization and inhibiting TAK1 activation. *Cell Rep* 3:1690–1702. <https://doi.org/10.1016/j.celrep.2013.03.039>.
  63. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
  64. Munera D, Ritchie JM, Hatzios SK, Bronson R, Fang G, Schadt EE, Davis BM, Waldor MK. 2014. Autotransporters but not pAA are critical for rabbit colonization by Shiga toxin-producing *Escherichia coli* O104:H4. *Nat Commun* 5:3080. <https://doi.org/10.1038/ncomms4080>.
  65. Knutton S, Baldwin T, Williams PH, McNeish AS. 1989. Actin accumulation at sites of bacterial adhesion to tissue culture cells: basis of a new diagnostic test for enteropathogenic and enterohemorrhagic *Escherichia coli*. *Infect Immun* 57:1290–1298.